FrancophonIA/ELRC3.0 huggingface dataset:
English: Further information on Ixiaro can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Ixiaro.
Estonian: Lisateave Ixiaro kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Ixiaro.
English: • The third main study involved 1,869 children aged between 2 months and 18 years.
Estonian: • Kolmandas põhiuuringus osales 1869 last vanuses 2 kuud kuni 18 aastat.
English: What measures are being taken to ensure the safe and effective use of Ixiaro?
Estonian: Mis meetmed võetakse, et tagada Ixiaro ohutu ja efektiivne kasutamine?
English: The second dose should be given at least one week before potential exposure to the virus.
Estonian: Teine annus tuleb manustada vähemalt üks nädal enne võimalikku kokkupuudet viirusega.
English: The European Medicines Agency decided that Ixiaro's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Ixiaro kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The 7-day accelerated vaccination course did not produce lower protection than the standard 4-week vaccination course.
Estonian: 7-päevane kiirvaktsineerimine ei põhjustanud nõrgemat kaitset kui 4-nädalane tavavaktsineerimine.
English: Other information about Ixiaro
Estonian: Muu teave Ixiaro kohta
English: It is transmitted by mosquitoes and is most common in Asia, particularly in rural areas.
Estonian: Haigust kannavad edasi sääsed ja enamasti esineb haigus Aasias, eelkõige maapiirkondades.
English: This was compared with 94% of the people receiving the comparator vaccine (347 out of 370).
Estonian: Võrdlusvaktsiiniga vaktsineeritutest oli selliseid 94% (347 inimest 370st).
English: Children and adolescents may also receive a booster dose one to two years after the initial vaccination.
Estonian: Lapsed ja noorukid tohivad samuti saada korduvannuse 1-2 aastat pärast algset vaktsineerimist.
English: Ixiaro (Japanese encephalitis vaccine (inactivated, adsorbed))
Estonian: Ixiaro (Jaapani entsefaliidi vaktsiin (inaktiveeritud, adsorbeeritud))
English: As for all medicines, data on the use of Ixiaro are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Ixiaro kasutamise kohta pidevat järelevalvet.
English: This means that the virus is fixed onto aluminium compounds, to stimulate a better response.
Estonian: See tähendab, et viirus on parema immuunvastuse tekitamiseks kinnitatud alumiiniumiühenditele.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ixiaro have been included in the summary of product characteristics and the package leaflet.
Estonian: Ixiaro ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The Agency noted that the production of the only other vaccine for protection against Japanese encephalitis that was in use outside Asia had been discontinued.
Estonian: Amet märkis, et on lõpetatud ainsa teise väljaspool Aasiat kasutatud Jaapani entsefaliidi eest kaitsva vaktsiini tootmine.
English: When a person is given the vaccine, the immune system identifies the inactivated virus as ‘foreign' and makes antibodies against it.
Estonian: Kui inimesele manustatakse vaktsiini, peab immuunsüsteem inaktiveeritud viirust võõraks ja tekitab selle vastu antikehi.
English: Side effects reported with Ixiaro are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ixiaro kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: • The second main study in 660 adults compared a rapid vaccination course (2 doses given 7 days apart) with the standard vaccination course (2 doses given 4 weeks apart).
Estonian: • Teises põhiuuringus, milles osales 660 täiskasvanut, võrreldi kiirvaktsineerimist (2 annust 7-päevase vahega) tavavaktsineerimisega (2 annust 4-nädalase vahega).
English: Before vaccination, most of the people in the study had no protective levels of antibodies against the virus.
Estonian: Enne vaktsineerimist ei olnud enamikul uuringus osalenutest viirusvastaseid antikehi kaitsvas koguses.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend against a disease.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi looduslikud kaitsemehhanismid) kaitsma organismi haiguse eest.
English: For more information about using Ixiaro, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Ixiaro kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: What is Ixiaro and what is it used for?
Estonian: Mis on Ixiaro ja milleks seda kasutatakse?
English: Vaccination with Ixiaro should be considered for people who are at risk of exposure to the Japanese encephalitis virus through travel or work.
Estonian: Ixiaroga vaktsineerimist tuleb kaaluda inimestel, kellel on reisimise või töö tõttu Jaapani entsefaliidi viirusega kokkupuute risk.
English: Japanese encephalitis can be fatal or lead to long-term disability.
Estonian: Jaapani entsefaliit võib lõppeda surmaga või tekitada pikaajalise puude.
English: The virus in Ixiaro is grown in mammal cells (‘Vero cells') under laboratory conditions.
Estonian: Ixiaros sisalduvat viirust kasvatatakse laboritingimustes imetajate rakkudes (nn Vero rakud).
English: In addition, the company presented the results of studies looking at the level of protection in adults and in children for up to 3 years after vaccination with Ixiaro, and at the response to booster doses.
Estonian: Peale selle esitas turustaja uuringute tulemused, milles vaadeldi kaitsetaset täiskasvanutel ja lastel kuni 3 aasta jooksul pärast Ixiaroga vaktsineerimist ning reaktsiooni korduvannustele.
English: • The first study involved 867 healthy adults and compared Ixiaro with another vaccine for Japanese encephalitis containing viruses grown in mouse brains.
Estonian: • Esimeses uuringus, milles osales 867 tervet täiskasvanut, võrreldi Ixiarot teise Jaapani entsefaliidi vaktsiiniga, mis sisaldas hiire ajus kasvatatud viirust.
English: These additional studies showed that protection against Japanese encephalitis virus lasted for at least 2 to 3 years in most people vaccinated with Ixiaro.
Estonian: Lisauuringud tõendasid, et kaitse Jaapani entsefaliidi viiruse vastu kestis enamikul Ixiaroga vaktsineeritutel vähemalt 2-3 aastat.
English: In adults, the second dose can be given up to 11 months after the first.
Estonian: Teise annuse tohib manustada täiskasvanutele kuni 11 kuu jooksul pärast esimest annust.
English: In adults, including those aged above 65 years, and children aged 3 years and older, a full dose of Ixiaro (0.5 ml) should be given, and an additional 0.5 ml dose should be given four weeks later.
Estonian: Täiskasvanutele, sh üle 65-aastastele, ja vähemalt 3-aastastele lastele tuleb manustada Ixiaro täisannus (0,5 ml) ning 4 nädala pärast lisaannus (0,5 ml).
English: Adults from 18 to 65 years can also receive a rapid vaccination course, where the second dose is given seven days after the first dose.
Estonian: 18-65-aastastele täiskasvanutele tohib teha ka kiirvaktsineerimist, mille korral manustatakse teine annus 7 päeva pärast esimest.
English: Ixiaro contains small amounts of the virus that causes Japanese encephalitis, which has been inactivated (killed) so that it cannot cause the disease.
Estonian: Ixiaro sisaldab väheses koguses Jaapani entsefaliidi viirust, mis on inaktiveeritud (surmatud), nii et see ei saa haigust tekitada.
English: The most common side effects with Ixiaro in adults (which may affect more than 1 in 10 people) are headache, myalgia (muscle pain), pain and tenderness at the injection site and tiredness.
Estonian: Täiskasvanutel on Ixiaro kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) peavalu, müalgia (lihasevalu), süstekoha valu ja valulikkus ning väsimus.
English: Four weeks after the final injection, 96% of these people who received both doses of Ixiaro had developed protective levels of antibodies (352 out of 365).
Estonian: Viimasest süstist 4 nädala möödumisel oli Ixiaro mõlema annuse saanutest neid, kellel tekkis kaitsvas koguses antikehi, 96% (352 inimest 365st).
English: A booster dose should also be considered for adults aged above 65 years before any further exposure to the Japanese encephalitis virus.
Estonian: Korduvannust tuleb kaaluda ka üle 65-aastastel enne nende võimalikku kokkupuudet Jaapani entsefaliidi viirusega.
English: What are the risks associated with Ixiaro?
Estonian: Mis riskid Ixiaroga kaasnevad?
English: In children aged between 2 months and 3 years, half the adult dose of Ixiaro (0.25 ml) should be given, and an additional 0.25 ml dose should be given four weeks later.
Estonian: 2 kuu kuni 3 aasta vanustele lastele tuleb manustada pool Ixiaro täiskasvanu annust (0,25 ml) ning 4 nädala pärast tuleb manustada lisaannus (0,25 ml).
English: Adults from 18-65 years who are likely to be exposed to the Japanese encephalitis virus again or who are at continuous risk of the disease should receive a booster dose of Ixiaro one to two years later and a second booster dose 10 years after the first booster.
Estonian: 18-65-aastastele täiskasvanutele, kes tõenäoliselt puutuvad Jaapani entsefaliidi viirusega uuesti kokku või kellel on pidev kokkupuuterisk, tuleb 1-2 aasta pärast manustada esimene korduvannus ja 10 aastat pärast esimest teine korduvannus.
English: Ixiaro must not be used in people who are hypersensitive (allergic) to any residual substances in the vaccine such as protamine sulphate.
Estonian: Ixiarot ei tohi kasutada patsiendid, kes on ülitundlikud (allergilised) vaktsiini mis tahes jääkainete suhtes (näiteks protamiinsulfaat).
English: How does Ixiaro work?
Estonian: Kuidas Ixiaro toimib?
English: For the full list of side effects of Ixiaro, see the package leaflet.
Estonian: Ixiaro kõrvalnähtude täielik loetelu on pakendi infolehel.
English: They also showed that a booster dose might be needed to maintain high levels of protection, which may be necessary for people at high risk of exposure to the virus.
Estonian: Samuti tõendati uuringutes, et viirusega kokkupuute suure riskiga isikud võivad suurema kaitsetaseme saavutamiseks vajada korduvvaktsineerimist.
English: Anyone who has an allergic reaction after the first dose of Ixiaro should not receive the second dose.
Estonian: Kui Ixiaro esimene annus tekitab allergilise reaktsiooni, ei tohi teist annust manustada.
English: Ixiaro is a vaccine that helps protect adults and children aged 2 months and older against Japanese encephalitis, a disease that causes inflammation of the brain.
Estonian: Ixiaro on vaktsiin, mida kasutatakse täiskasvanute ja vähemalt 2-kuuste laste kaitseks Jaapani entsefaliidi (peaaju põletikku tekitava haiguse) eest.
English: What benefit of Ixiaro have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ixiaro kasulikkus?
English: An overview of Ixiaro and why it is authorised in the EU
Estonian: Ülevaade ravimist Ixiaro ja ELis müügiloa väljastamise põhjendus
English: Ixiaro can only be obtained with a prescription.
Estonian: Ixiaro on retseptiravim.
English: How is Ixiaro used?
Estonian: Kuidas Ixiarot kasutatakse?
English: In children, fever, diarrhoea, influenza-like illness, irritability, and reactions at the injection site (such as redness,
Estonian: Lastel on kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 lapsel 10st) palavik, kõhulahtisus, gripilaadne haigus, ärrituvus ning süstekoha reaktsioonid (näiteks punetus, valu ja valulikkus).
English: It is recommended that individuals who receive the first dose of Ixiaro should receive both doses.
Estonian: Ixiaro esimese annuse saanud isikutele on soovitatav manustada ka teine annus.
English: 99% to 100% of children who received both doses of Ixiaro had developed protective levels of antibodies against the Japanese encephalitis virus 4 weeks after the final injection.
Estonian: Mõlemad Ixiaro annused saanud lastest oli neid, kellel tekkis 4 nädalat pärast viimast vaktsineerimist kaitsev kogus antikehi Jaapani entsefaliidi viiruse vastu, 99-100%.
English: Ixiaro is given by injection into a muscle, preferably into the shoulder muscle, or into the thigh muscle in young children.
Estonian: Vaktsiini süstitakse lihasesse, eelistatavalt deltalihasesse (õlavarde) või väikelastel reielihasesse.
English: In future, the immune system will be able to produce antibodies quickly and in large numbers when it is exposed to Japanese encephalitis virus again.
Estonian: Kui immuunsüsteem puutub hiljem Jaapani entsefaliidi viirusega uuesti kokku, tekib kiiresti palju antikehi.
English: On average, the levels of antibodies were over 2 times higher in the people receiving Ixiaro than in those receiving the comparator vaccine.
Estonian: Ixiarot saanutel oli antikehade sisaldus keskmiselt üle 2 korra suurem kui võrdlusvaktsiini saanutel.
English: Ixiaro (given as 2 doses 4 weeks apart) was as effective as the comparator vaccine at triggering the production of antibodies against the Japanese encephalitis virus.
Estonian: 4-nädalase vahega 2 annusena manustatud Ixiaro tekitas Jaapani entsefaliidi viiruse vastaseid antikehi sama efektiivselt kui võrdlusvaktsiin.
English: Ixiaro has been shown to trigger the production of antibodies against the Japanese encephalitis virus in 3 main studies:
Estonian: 3 põhiuuringus tõendati, et Ixiaro vallandab antikehade tekke Jaapani entsefaliidi viiruse vastu.
English: Ixiaro can be injected under the skin in people who have a bleeding disorder such as low blood platelet counts or haemophilia.
Estonian: Patsientidel, kellel on hüübimishäired, näiteks trombotsüütide (vereliistakute) vaegus või hemofiilia, tohib Ixiarot süstida naha alla.
English: 20 May 2019
Estonian: 20. mai 2019
English: What is closantel?
Estonian: Mis on klosanteel?
English: The European Commission issued a decision on 20 May 2019.
Estonian: Euroopa Komisjon tegi otsuse 20. mail 2019.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/126)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/126) tulemused
English: In addition, cattle may also be treated topically on their skin.
Estonian: Peale selle võib veiseid ravida paikselt naha kaudu.
English: Consequently, on 5 February 2018, the United Kingdom initiated a procedure under Article 35 of Directive 2001/82/EC for the aforementioned veterinary medicinal products.
Estonian: Seetõttu algatas Ühendkuningriik eespool nimetatud veterinaarravimite kohta 5. veebruaril 2018 direktiivi 2001/82/EÜ artikli 35 kohase menetluse.
English: Withdrawal period refers to the minimum period of time from administering the last dose of veterinary medicinal product and the production of meat or other animal-derived products for food.
Estonian: Keeluaeg on minimaalne aeg, mis peab jääma veterinaarravimi viimase annuse manustamisest liha või muude loomset päritolu toodete toiduks tootmiseni.
English: The CVMP recommended that variations to the terms of the marketing authorisations for the aforementioned veterinary medicinal products are required in order to amend the product information accordingly.
Estonian: Veterinaarravimite komitee soovitas muuta eespool nimetatud veterinaarravimite müügilubade tingimusi, et muuta vastavalt nende ravimiteavet.
English: Why were solutions for injection containing 50 mg closantel per ml (as a single active substance) reviewed?
Estonian: Miks vaadati läbi 50 mg/ml klosanteeli (ainsa toimeainena) sisaldavad süstelahused?
English: On 21 February 2019, the European Medicines Agency (the Agency) completed a review of the consumer safety of the withdrawal periods (meat and offal) for sheep for veterinary medicinal products containing 50 mg closantel per ml (as a single active substance) presented as solutions for injection.
Estonian: 21. veebruaril 2019 lõpetas Euroopa Ravimiamet (edaspidi „amet“) läbivaatamismenetluse, mis käsitles lammastele (liha ja rups) kehtestatud keeluaegade tarbijaohutust 50 mg/ml klosanteeli (ainsa toimeainena) sisaldavate veterinaarravimite korral, mida kasutatakse süstelahusena.
English: Closantel is intended for use in cattle and sheep for the treatment and control of adult and immature flukes, nematodes and larval stages of some arthropods and is administered subcutaneously by injection or as an oral solution.
Estonian: Klosanteel on ette nähtud kasutamiseks veistel ja lammastel täiskasvanud maksakaanide ja nende vastsete, ümarusside ja teatud lülijalgsete vastsestaadiumide vastaseks raviks ja tõrjeks ning seda manustatakse subkutaanse süstena või suukaudse lahusena.
English: The CVMP was requested to review all available residue depletion data and recommend withdrawal periods for meat and offal derived from treated sheep.
Estonian: Veterinaarravimite komiteel paluti läbi vaadata kõik olemasolevad ravimijääkide kadumise andmed ning soovitada ravitud lammaste liha ja rupsi keeluajad.
English: The United Kingdom noted that, for veterinary medicinal products containing closantel presented as solutions for injection, there are different approved withdrawal periods for sheep across the European Union e.g. sheep meat and offal, from 28 days to 107 days.
Estonian: Ühendkuningriik märkis, et süstelahusena kasutatavate klosanteeli sisaldavate veterinaarravimite korral lammaste (näiteks lammaste liha ja rupsi) jaoks heakskiidetud keeluajad Euroopa Liidus on erinevad, st 28 päevast 107 päevani.
English: Based on the evaluation of the currently-available data, the CVMP concluded that the overall benefitrisk balance for veterinary medicinal products containing 50 mg closantel per ml (as a single active substance) presented as solutions for injection for subcutaneous use in sheep, is positive and agreed that the withdrawal periods (meat and offal) for sheep should be harmonised and amended to provide assurance for consumer safety.
Estonian: Tuginedes praegu kättesaadavate andmete hindamisele, järeldas veterinaarravimite komitee, et lammastel subkutaanse süstelahusena kasutatavate 50 mg/ml klosanteeli (ainsa toimeainena) sisaldavate veterinaarravimite üldine kasulikkuse ja riski suhe on positiivne, ja nõustus, et lammaste (liha ja rups) keeluaegu tuleb tarbijaohutuse tagamiseks ühtlustada ja muuta.
English: Proprietary data and scientific references on residue depletion were provided by the marketing authorisation holders.
Estonian: Müügilubade hoidjad esitasid ravimijääkide organismist kadumise kohta avaldamata andmed ja teaduskirjanduse viited.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the overall benefit-risk balance for the concerned products is positive and recommended amendments to the withdrawal periods for sheep to provide assurance for consumer safety.
Estonian: Ameti veterinaarravimite komitee järeldas, et asjaomaste veterinaarravimite üldine kasulikkuse ja riski suhe on positiivne, ning soovitas tarbijaohutuse tagamiseks muuta lammastele kehtestatud keeluaegu.
English: Greece 17456
Estonian: Kreeka 17456
English: Agios Dimitrios 17341 Greece
Estonian: Agios Dimitrios 17341 Kreeka
English: Markopoulo Mesogeion 19003 Greece
Estonian: Markopoulo Mesogeion 19003 Kreeka
English: 747 70 Opava-Komárov Czech Republic
Estonian: 747 70 Opava-Komárov Tšehhi Vabariik
English: Rivium Westlaan 142 2909 LD Capelle a/d Ijssel The Netherlands
Estonian: Rivium Westlaan 142 2909 LD Capelle a/d Ijssel Holland
English: Osa Mayor, 4Area BAravaca 28023 (Madrid) Spain
Estonian: Osa Mayor, 4Area BAravaca 28023 (Madrid) Hispaania
English: MYLAN BVBA/SPRL Terhulpsesteenweg 6A 1560 Hoeilaart Belgium
Estonian: MYLAN BVBA/SPRL Terhulpsesteenweg 6A 1560 Hoeilaart Belgia
English: Ratiopharm Nederland BV Ronde Tocht 11
Estonian: NL - Holland Ratiopharm Nederland BV Ronde Tocht 11
English: ES - Spain BEXAL FARMACEUTICA, S.ACentro Empresarial Osa Mayor.
Estonian: ES - Hispaania BEXAL FARMACEUTICA, S.ACentro Empresarial Osa Mayor.
English: Pärnu mnt 139E/ 211317 Tallinn Estonia
Estonian: Pärnu mnt 139E/2 11317 Tallinn Eesti
English: B-dul Theodor Pallady nr. 44C Sector 3, Bucureşti Romania
Estonian: B-dul Theodor Pallady nr. 44C Sector 3, Bucureşti
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states
Estonian: Lisa I Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside, müügiloa hoidjate loetelu liikmesriikides
English: 191 90 Sollentuna Sweden
Estonian: 191 90 Sollentuna Rootsi
English: 7720 Pécsvárad Hungary
Estonian: 7720 Pécsvárad Ungari
English: Alternova A/S Lodhusvej 11 4230 Skælskør Denmark
Estonian: Alternova A/S Lodhusvej 11 4230 Skælskør Taani
English: SI-1000 Ljubljana Slovenia
Estonian: SI-1000 Ljubljana
English: 81105 Bratislava Slovakia
Estonian: 81105 Bratislava
English: IS - Iceland Pfizer Aps Lautrupsvang 8
Estonian: IS - Island Pfizer Aps Lautrupsvang 8
English: IE - Ireland Pfizer Healthcare Ireland 9 Riverwalk
Estonian: Pfizer Healthcare Iirimaa 9 Riverwalk
English: PL - Poland Grodziskie Zakłady Farmaceutyczne "Polfa" Sp. z o.o.
Estonian: Grodziskie Zakłady Farmaceutyczne "Polfa" Sp. z o.o.
English: ES - Spain NOVARTIS FARMACEUTICA, S.A. Gran Via de les Corts Catalanes 764 Barcelona
Estonian: ES - Hispaania NOVARTIS FARMACEUTICA, S.A. Gran Via de les Corts Catalanes 764 Barcelona
English: IT - Italy Salus Researches Spa Via Aurelia, 58
Estonian: Salus Researches Spa Via Aurelia, 58
English: 97-107 Uxbridge Road EALING, LONDON W5 5TL United Kingdom
Estonian: 97-107 Uxbridge Road EALING, LONDON W5 5TL Ühendkuningriik
English: S.C. VIM SPECTRUM S.R.L., Şoseaua Sighişoarei, Nr. 409, Corunca, jud Mureş Romania
Estonian: RO - Rumeenia S.C. VIM SPECTRUM S.R.L., Şoseaua Sighişoarei, Nr. 409, Corunca, jud Mureş
English: 2750 Ballerud Denmark
Estonian: 2750 Ballerud
English: Eurogenerics SA Esplanade Heysel, B22 B- 1020 Bruxelles Belgium
Estonian: Eurogenerics SA Esplanade Heysel, B22 B- 1020 Bruxelles Belgia
English: S. C. LABORMED PHARMA S. A. Splaiul Independenţei nr. 319 E Sector 6
Estonian: RO - Rumeenia S. C. LABORMED PHARMA S. A. Splaiul Independenţei nr. 319 E Sector 6
English: SO18 3JD
Estonian: Southampton SO18 3JD
English: DK-5220 Odense SØ Denmark
Estonian: DK-5220 Odense SØ Taani
English: ACTAVIS UK LIMITED WHIDDON VALLEY BARNSTAPLE DEVON EX32 8NS United Kingdom
Estonian: ACTAVIS UK LIMITED WHIDDON VALLEY BARNSTAPLE DEVON EX32 8NS Ühendkuningriik
English: capsules (with micronised powder)
Estonian: kapslid (mikroniseeritud pulbriga)
English: FR - France Pfizer Holding France 23-25, avenue du Docteur Lannelongue
Estonian: Pfizer Holding Prantsusmaa 23-25, avenue du Docteur Lannelongue
English: SANDOZ LIMITED 37 Woolmer Way, Borden, Hampshire GU35 9QE United Kingdom
Estonian: SANDOZ LIMITED 37 Woolmer Way, Borden, Hampshire GU35 9QE Ühendkuningriik
English: UAB Sanofi - Aventis Lietuva A. Juozapaviciaus 6/2 LT-09310 Vilnius Lithuania
Estonian: UAB Sanofi - Aventis Lietuva A. Juozapaviciaus 6/2 LT-09310 Vilnius Leedu
English: 920 27 Hlohovec Slovac Republic
Estonian: 920 27 Hlohovec Slovakkia Vabariik
English: Korinthos 20100
Estonian: Korinthos 20100 Kreeka
English: de Europa, 20 B. Parque Empresarial La Moraleja Alcobendas MADRID Spain
Estonian: de Europa, 20 B. Parque Empresarial La Msuukaudneeja Alcobendas MADRID Hispaania
English: IT - Italy Boniscontro & Gazzone Srl Via Pavia, 6
Estonian: Boniscontro & Gazzone Srl Via Pavia, 6
English: ES - Spain USO RACIONAL S.L.Ferraz, 10 - 1º Izda.
Estonian: ES - Hispaania USO RACIONAL S.L.Ferraz, 10 - 1º Izda.
English: Generics (Uk) Limited Station Close Potters Bar, HERTS EN6 1TL United Kingdom
Estonian: Generics (Uk) Limited Station Close Potters Bar, HERTS EN6 1TL Ühendkuningriik
English: Genus Pharmaceuticals Limited Park View House 65 London Road NEWBURY, BERKS RG14 1JN United Kingdom
Estonian: Genus Pharmaceuticals Limited Park View House 65 London Road NEWBURY, BERKS RG14 1JN Ühendkuningriik
English: ES - Spain LABORATORIO STADA, S.L.Frederic Mompou, 5 Sant Just Desvern08960
Estonian: ES - Hispaania LABORATORIO STADA, S.L.Frederic Mompou, 5 Sant Just Desvern08960